Paul Carter
Director/Board Member at HUTCHMED (CHINA) LIMITED
Net worth: 677 259 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John F. Donovan | M | - |
Concentric Analgesics, Inc.
 Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 years |
| Per Lundin | M | 41 |
Evox Therapeutics Ltd.
 Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 years |
| Murray Stewart | M | 63 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 21 years |
| Craig O. Husfeld | M | - |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 years |
| Anthony Tennyson | M | - | 4 years | |
| Jonathan Held | M | 38 | 4 years | |
| Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 years |
| Edith Shih | F | 71 | 24 years | |
| John McHutchison | M | 66 |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 13 years |
| Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Wei Guo Su | M | 66 | 19 years | |
| Frank J. Bellizzi | M | 58 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 10 years |
| Harpreet Singh-Jasuja | M | 50 | 24 years | |
| Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 years |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Jeremy Charles Green | M | 49 | 6 years | |
| Stephen P. Squinto | M | 67 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 years |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 years |
| Shu Kam Mok | M | 63 | 7 years | |
| Mark Lee | M | 46 | - | |
| Matthew Wood | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 years |
| Steffen Walter | M | 47 | 4 years | |
| James Ford | M | - | 29 years | |
| John Papastergiou | M | - | - | |
| Gordo Whittaker | M | - | - | |
| Derek Belz | M | - | 2 years | |
| George Scorsis | M | - | - | |
| Michael Atieh | M | 70 | 4 years | |
| Thomas King | M | 69 |
Concentric Analgesics, Inc.
Concentric Analgesics, Inc. Packaged SoftwareTechnology Services Concentric Analgesics, Inc. develops novel, non-opioid therapeutics for the management of acute postsurgical and chronic osteoarthritis pain. The company was founded by John F. Donovan, Frank J. Bellizzi and Craig O. Husfeld in 2014 and is headquartered in San Francisco, CA. | 7 years |
| Bryan Reasons | M | 56 | 5 years | |
| Chi Keung To | M | 72 | 24 years | |
| Chig Fung Cheng | M | 57 | 16 years | |
| Stephen Page | M | - | - | |
| Heather Mason | F | 63 | 4 years | |
| Graeme Jack | M | 73 | 7 years | |
| Andrew Dickinson | M | 54 | 8 years | |
| Sarah Gordon-Wild | F | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| David Nutt | M | - | - | |
| Miriam Meyer | M | - | 15 years | |
| Ephraim Hofsäß | M | - | 5 years | |
| Timothy Woodthorpe | M | - | 24 years | |
| James Collins | M | - | - | |
| Yiling Cui | F | - | - | |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Edward Sturchio | M | - | 4 years | |
| Dan Eldar | M | 70 | 8 years | |
| Amrit Nagpal | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | - |
| Roger K. Cady | M | - | 8 years | |
| Jordan Silverstein | M | - | 5 years | |
| Adam Stoten | M | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | 8 years |
| Michael Leung | M | - | 24 years | |
| Rainer Kramer | M | 60 | 12 years | |
| Charles Nixon | M | 54 | 18 years | |
| May Wang | M | 60 | 14 years | |
| Naomi Junghae | F | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Mark Litton | M | 56 | 14 years | |
| Randall Schatzman | M | 69 | 14 years | |
| Alan Montgomery | M | 70 | 13 years | |
| Mark Trudeau | M | 62 | 9 years | |
| Paul Cleveland | M | 67 | - | |
| Matthew Harbaugh | M | 53 | 6 years | |
| Christian Hogg | M | 58 | 16 years | |
| Angus Russell | M | 68 | 8 years | |
| Melissa Yeager | F | - | 10 years | |
| Robert Azelby | M | 56 | 1 years | |
| Kevin Chow | M | 54 | 7 years | |
| Benjamin Sessa | M | - | - | |
| Christopher Huang | M | 72 | 11 years | |
| Larry K. Benedict | M | 63 | 11 years | |
| Peter Bisgaard | M | 50 | 3 years | |
| Anne Michelle Whitaker | F | 56 | 4 years | |
| Daniel A. Celentano | M | 72 | 1 years | |
| David Walsey | M | - | - | |
| John Latham | M | 64 | 15 years | |
| Riad El-Dada | M | 59 | 1 years | |
| Wouter Joustra | M | 35 | 1 years | |
| Kate Butler | F | - | 5 years | |
| Carlos Paya | M | 65 | 3 years | |
| Gordon Earle Moore | M | 95 | 17 years | |
| Gary Bridger | M | 61 | 3 years | |
| Paul Bisaro | M | 63 | 1 years | |
| Woodrow Myers | M | 70 | 1 years | |
| JoAnn Reed | F | 68 | 9 years | |
| J. Carroll | M | 74 | 9 years | |
| Eric Carter | M | 72 | 1 years | |
| David Norton | M | 72 | 5 years | |
| Melvin Booth | M | 79 | 5 years | |
| Kneeland Youngblood | M | 69 | 9 years | |
| James Sulat | M | 73 | 1 years | |
| Clay Siegall | M | 63 | 14 years | |
| David Carlucci | M | 69 | 9 years | |
| Robert Wilson | M | 81 | 11 years | |
| John David Coombe | M | 79 | 5 years | |
| Neal Goldman | M | 54 | 1 years | |
| Stephen M. Dow | M | 68 | 13 years | |
| Wendy Yarno | F | 69 | - | |
| Deepa Pakianathan | M | 59 | 6 years | |
| Michael William Davis Howell | M | 76 | 11 years | |
| Diane Gulyas | F | 67 | 5 years | |
| Patrick Malloy | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 27 | 27.00% |
| Ireland | 20 | 20.00% |
| Hong Kong | 15 | 15.00% |
| United Kingdom | 12 | 12.00% |
| Canada | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Carter
- Personal Network
